Ypsomed is a global leading company of injection systems for self-medication. After supplying products to China for over 15 years and considering the growth potential of the market, Ypsomed has decided to open its first production facility in China, investing over CHF 35 million (over 270 million RMB) in the first phase.
“The Chinese market is growing rapidly, and the number of our local customer projects is constantly increasing. Due to this growth potential, the establishment of a local production facility is obvious for us. We are not moving capacity out of Europe but expanding it. With our new production plant in China, we are closer to our Chinese customers and shorten the supply chains considerably, which will also have less of an impact on our carbon footprint,” says CEO Simon Michel, explaining the move to China.